Castle Biosciences (NASDAQ:CSTL) Insider Sells $49,945.39 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 1,301 shares of Castle Biosciences stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $38.39, for a total transaction of $49,945.39. Following the completion of the sale, the insider directly owned 77,694 shares in the company, valued at approximately $2,982,672.66. This represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Up 5.1%

CSTL opened at $32.03 on Friday. Castle Biosciences, Inc. has a twelve month low of $17.72 and a twelve month high of $44.28. The company’s 50-day moving average price is $23.77 and its two-hundred day moving average price is $26.20. The stock has a market cap of $978.52 million, a price-to-earnings ratio of -48.53 and a beta of 0.98. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. The company had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. As a group, equities analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Institutional Trading of Castle Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. purchased a new position in shares of Castle Biosciences during the 4th quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Castle Biosciences in the fourth quarter worth $35,000. Global Retirement Partners LLC purchased a new stake in shares of Castle Biosciences in the second quarter worth $26,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Castle Biosciences by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after buying an additional 297 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Castle Biosciences by 140.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock valued at $68,000 after buying an additional 1,022 shares during the period. Institutional investors own 92.60% of the company’s stock.

Key Headlines Impacting Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and reiterated a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and indicates potential upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest earnings exceeded expectations. Revenue was $99.86 million versus the $86.23 million consensus estimate, while the company reported a per-share loss of $0.07 compared with the expected $0.41 loss. Although CSTL remains unprofitable, the narrower-than-expected loss and stronger revenue support an improving operating outlook.
• Neutral Sentiment: Institutional investors own approximately 92.6% of CSTL’s shares. Recent purchases or stake increases by firms including AQR Capital Management, Amundi, Legal & General and Mirae Asset may provide shareholder support, but these ownership changes are not necessarily immediate trading catalysts.
• Negative Sentiment: Several company insiders disclosed sizable stock sales. Derek J. Maetzold sold more than 39,000 shares for approximately $1.21 million in August 4–5 transactions, while COO Kristen Oelschlager sold 8,586 shares worth about $256,000. Tobin W. Juvenal separately sold 1,301 shares for roughly $50,000. The sales reduced the insiders’ positions and could pressure sentiment, particularly following CSTL’s recent advance. However, all of the reported transactions were executed under pre-arranged Rule 10b5-1 trading plans, making them a less definitive bearish signal. Castle Biosciences insider sales

Wall Street Analyst Weigh In

A number of research firms have issued reports on CSTL. Robert W. Baird set a $36.00 target price on Castle Biosciences in a research report on Friday, July 31st. BTIG Research upped their price target on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. KeyCorp set a $35.00 price target on Castle Biosciences in a research note on Friday, May 29th. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Zacks Research cut Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.